Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.
In their findings (reported in The Lancet Infectious Diseases), they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
The authors report from a Phase IIb randomised, controlled, double-blind trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso. A total of 450 participants aged five to 17 months were recruited from the catchment area of Nanoro, with 409 receiving the booster.
The participants were randomly assigned to three groups, with the first two groups receiving the R21/Matrix-M (with either a low dose or high dose of the Matrix-M adjuvant) vaccine as a booster and the third a rabies vaccine as the control group. Each child received the same booster vaccination as their primary series of vaccinations. Doses were administered in June 2020, largely prior to the peak malaria season.
The researchers report a vaccine efficacy of 80% in the higher-dose adjuvant group, and 70% in the lower dose adjuvant group, over 12 months of follow-up. Antibody levels were restored to similar levels as those following the primary vaccinations 28 days after the booster doses were administered. No serious adverse events related to the vaccine were noted.
Halidou Tinto, Professor in Parasitology, Regional Director of IRSS in Nanoro, and the trial Principal Investigator, said: ‘It is fantastic so see such high efficacy again after a single booster dose of vaccine. We are currently part of a very large phase III trial aimed at licensing this vaccine for widespread use next year.’
Professor Adrian Hill, the University of Oxford’s Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology, and co-author of the paper, said: ‘We are delighted to find that a standard four dose immunisation regime can now, for the first time, reach the high efficacy level over two years that has been an aspirational target for malaria vaccines for so many years.’
The R21/Matrix-M™ malaria vaccine candidate created by the University of Oxford includes Novavax’ proprietary saponin-based Matrix-M adjuvant and is licensed to Serum Institute of India.
The trial – funded by the EDCTP2 programme supported by the European Union (grant number RIA2016V-1649-MMVC) as well as the Wellcome Trust and NIHR Oxford Biomedical Research Centre – has been extended for another two years to assess if further booster doses will be necessary to maintain high efficacy over time.
Results from the key ongoing Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged five to 36 months across four African countries, are also expected later this year.
Gareth Jenkins, Director of Advocacy at Malaria No More UK said: ‘Today’s R21 vaccine results from Oxford’s renowned Jenner Institute are another encouraging signal that, with the right support, the world could end child deaths from malaria in our lifetimes.
‘But for new British inventions to achieve their potential, British leadership must continue, not least at the imminent US-hosted Global Fund to Fight AIDS, Tuberculosis and Malaria replenishment conference this September.
‘This will be the new PM’s first foreign policy test – for the sake of millions of children’s lives, global health security, and British relations with its closest ally, it’s a test they cannot fail.’
More from: University of Oxford
The Latest Updates from Bing News
Go deeper with Bing News on:
- Malaria vaccine trials in Africa confirm high efficacy
The phase 3 double-blinded, randomised trials of the malaria vaccine R21/Matrix-M™, developed by Oxford University and Serum Institute of India, that were conducted among 4,800 children in Burkina ...
- Malaria Vaccine: Why is it Taking so Long?
Given this not very promising scenario why do we continue to believe that development of a malaria vaccine is possible?  There are several reasons to believe that malaria vaccine development ...
- Malaria Vaccine, a New Hope for Many Africans
Did you know that malaria kills one child every two minutes in Africa? This deadly disease has been a constant threat to human health and development for centuries, affecting millions of people across ...
- Malaria 'could be eliminated within a decade' thanks to game-changing British jabs
Top vaccinologist Prof Adrian Hill said the malaria field has "never been like this before" as he called for investment to achieve elimination.
- Malaria vaccine shortfall, heavy cost of Africa’s child deaths all thanks to global complacency
Where is the global commitment? One would think that institutions such as Unicef and Gavi, The Vaccine Alliance would be moving at maximum speed to deploy the new malaria vaccines. After all, this is ...
Go deeper with Bing News on:
- Ask A Doctor: How Does Rain Affect The Transmission Of Malaria?
This article examines the impact of rain on the transmission of malaria. Expert opinion from Dr. Alan Thomas Charly is presented, discussing the various ways in which rain can affect the transmission ...
- Nigerian govt seeks strategy overhaul to tackle malaria scourge
The Federal Government has called for a review of the country’s strategies to combat the malaria burden. The Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, made this call ...
- FG calls for strategy overhaul to combat malaria scourge
Ali Pate The Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, has called for a review of the country’s strategies to combat the malaria burden. He said this when partners ...
- The World Is Losing Its Fight Against Malaria
The world is losing its fight against malaria, a disease that has a devastating toll in Asia and Africa and is showing up in developed countries like the US. And a single business decision taken by ...
- Malaria Rates Surge After Mosquito Net Changes Complicate Global Fight
The world is losing its fight against malaria, a disease that has a devastating toll in Asia and Africa and is showing up in developed countries like the US. A single business decision taken by one of ...